LoA Update: Arrowhead’s Phase I/II ARO-HSD chances of progressing to next stage of development rises by five points after positive interim data

ARO-HSD is an RNA interference (RNAi) therapeutic that aims to reduce the mRNA and protein levels of hepatic HSD17B13. Credit: Emily frost/Shutterstock.com.

Arrowhead Pharmaceuticals’ ARO-HSD had its Phase Transition Success Rate (PTSR) increase by five points to 27% in nonalcoholic steatohepatitis (NASH) on the back of positive interim Phase I/II results. The data was presented at the virtual European Association of the Study of the Liver meeting this weekend. PTSR is the probability, given as a percentage, of a drug progressing successfully from one development stage to the next.

ARO-HSD is an RNA interference (RNAi) therapeutic that aims to reduce the mRNA and protein levels of hepatic HSD17B13, which would in turn reduce alanine aminotransferase (ALT). ALT is a liver enzyme elevated in liver diseases like NASH. In the Phase I/II trial (NCT04202354), in five patients with suspected NASH, their HSD17B13 mRNA was reduced by a mean of 84%, ranging from 62%–96%, as per a 23 June media release. HSD17B13 protein was reduced by at least 83% (abstract no LBP-2580).

The PTSR was updated on 25 June. ARO-HSD’s Likelihood of Approval (LoA) is static at 3%. LoA is identified via GlobalData’s analysis using a combination of machine learning and its proprietary algorithm. It is calculated by compounding the PTSR at each stage the drug is yet to progress through. Both LoA and PTSR can be calculated for a drug by considering characteristics like therapy area, indication and molecule type.

Arrowhead has a $8.97bn market cap.

Reynald Castaneda is an Associate Editor for Clinical Trials Arena parent company GlobalData’s investigative journalism team. A version of this article originally appeared on the Insights module of GlobalData’s Pharmaceutical Intelligence Center. To access more articles like this, visit GlobalData.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData

Tick here to opt out of curated industry news, reports, and event updates from Clinical Trials Arena.

Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.